Lecube Albert, Hernández Cristina, Simó Rafael
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Diabetes and Metabolism Research Unit, Institut de Recerca Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Diabetes Metab Res Rev. 2009 Jul;25(5):403-10. doi: 10.1002/dmrr.972.
Non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C virus (HCV) infection are major causes of liver disease frequently described in outpatient patients with glucose abnormalities. Hyperferritinemia, which suggests that iron overload plays a decisive role in the pathophysiology of insulin resistance and hyperglycemia, is a common finding in both disorders. However, the role of the hepatic iron deposition differs from one to the other. In NAFLD, a moderate liver iron accumulation has been observed and molecular mechanisms, including the downregulation of the liver iron exporter ferroportin-1, have been described. Iron overload will enhance intrahepatic oxidative stress that promotes hepatic fibrosis, interfere with insulin signalling at various levels and may hamper hepatic insulin extraction. Therefore, liver fibrosis, hyperglycemia and hyperinsulinemia will lead to increased levels of insulin resistance and the development of glucose abnormalities. Furthermore, iron depletion by phlebotomy removes liver iron content and reduces serum glucose and insulin resistance in NAFLD patients. Therefore, it seems that iron overload participates in those glucose abnormalities associated with NAFLD. Concerning chronic HCV infection, it has been classically assumed that iron overload contributes to insulin resistance associated with virus infection. However, recent evidence argues against the presence of iron overload in these patients and points to inflammation associated with diabetes as the main contributor to the elevated ferritin levels. Therefore, glucose abnormalities, and specially type 2 diabetes, should be taken into account when evaluating serum ferritin levels in patients with HCV infection.
非酒精性脂肪性肝病(NAFLD)和慢性丙型肝炎病毒(HCV)感染是门诊中经常被描述为伴有血糖异常的肝病的主要病因。高铁蛋白血症表明铁过载在胰岛素抵抗和高血糖的病理生理过程中起决定性作用,这在这两种疾病中均很常见。然而,肝脏铁沉积的作用在两者之间有所不同。在NAFLD中,已观察到肝脏有中度铁蓄积,并且已经描述了包括肝脏铁输出蛋白铁转运蛋白-1下调在内的分子机制。铁过载会增强肝内氧化应激,促进肝纤维化,在多个水平干扰胰岛素信号传导,并可能妨碍肝脏对胰岛素的摄取。因此,肝纤维化、高血糖和高胰岛素血症会导致胰岛素抵抗水平升高和血糖异常的发展。此外,通过放血进行铁消耗可降低NAFLD患者的肝脏铁含量,并降低血清葡萄糖和胰岛素抵抗。因此,铁过载似乎参与了与NAFLD相关的那些血糖异常。关于慢性HCV感染,传统上认为铁过载会导致与病毒感染相关的胰岛素抵抗。然而,最近的证据反驳了这些患者存在铁过载的观点,并指出与糖尿病相关的炎症是铁蛋白水平升高的主要原因。因此,在评估HCV感染患者的血清铁蛋白水平时,应考虑血糖异常,尤其是2型糖尿病。
J Gastroenterol Hepatol. 2005-2
Ital J Gastroenterol Hepatol. 1998-8
Free Radic Biol Med. 2007-2-1
Minerva Gastroenterol Dietol. 2006-6
Endocr Pract. 2022-5
World J Clin Cases. 2018-11-6
Int J Mol Sci. 2014-5-14
World J Gastroenterol. 2014-3-21
World J Gastroenterol. 2012-1-21
Hepatol Int. 2012-1